Medicaid expansion under the ACA improved long-term survival for younger adults with operable lung cancer, despite no earlier ...

About 40% of people with non-small cell lung cancer (NSCLC)—a type of cancer that begins in the tissues of your lungs—have metastatic disease at the time of their diagnosis. Metastatic NSCLC refers to ...

Researchers at the University of Michigan have identified a novel way to counter drug resistance in KRAS-mutant non-small ...

The nine minor health issues that could be early signs of lung cancer - As the NHS offers a ‘revolutionary’ blood test, here ...

In Brazil, the early detection of genetic alterations in lung cancer through liquid biopsies could be a valuable tool for expediting diagnoses and guiding patient treatment.

Thoracic medical oncologists and early drug development specialists at Memorial Sloan Kettering Cancer Center (MSK) continue to investigate new ways to improve outcomes for this patient population.

“We are encouraged by the emerging data from our lung cancer programs, where systemically delivered Olvi-Vec continues to ...

Trethera Corp. received a $2.7M NIH grant to study combining TRE-515 with KRAS inhibitors for lung cancer. Learn how this ...

The U.S. Food and Drug Administration has approved Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the first and only subcutaneously administered therapy for patients with epidermal growth ...